Beml Land Assets [BLAL] vs Johnson Pharmacare [JOHNPHARMA] Detailed Stock Comparison
Beml Land Assets
NSE
Loading...
Johnson Pharmacare
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Beml Land Assets wins in 7 metrics, Johnson Pharmacare wins in 7 metrics, with 1 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Beml Land Assets | Johnson Pharmacare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -231.69 | -79.00 | Beml Land Assets |
| Price-to-Book Ratio | 785.55 | 0.72 | Johnson Pharmacare |
| Debt-to-Equity Ratio | 779.28 | 1.08 | Johnson Pharmacare |
| PEG Ratio | -7.88 | 0.79 | Beml Land Assets |
| EV/EBITDA | -256.50 | -99.79 | Beml Land Assets |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | 127.68% | Johnson Pharmacare |
| EBITDA Margin (TTM) | N/A | 127.68% | N/A |
| Return on Equity | -337.59% | -1.04% | Johnson Pharmacare |
| Return on Assets (TTM) | -38.01% | -1.01% | Johnson Pharmacare |
| Free Cash Flow (TTM) | $8.34M | $-19.09M | Beml Land Assets |
| 1-Year Return | -24.16% | -40.91% | Beml Land Assets |
| Price-to-Sales Ratio (TTM) | N/A | -130.32 | N/A |
| Enterprise Value | $8.73B | $411.34M | Beml Land Assets |
| EV/Revenue Ratio | N/A | -123.38 | N/A |
| Revenue per Share (TTM) | $0 | $0 | Beml Land Assets |
| Earnings per Share (Diluted) | $-1.04 | $-0.01 | Johnson Pharmacare |
| Beta (Stock Volatility) | 0.21 | -0.90 | Johnson Pharmacare |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Beml Land Assets vs Johnson Pharmacare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beml Land Assets | 0.17% | 1.78% | -1.71% | 1.32% | 0.23% | -11.06% |
| Johnson Pharmacare | -1.27% | -1.27% | -9.30% | -14.29% | -21.21% | -30.97% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beml Land Assets | -24.16% | -15.27% | -15.27% | -15.27% | -15.27% | -15.27% |
| Johnson Pharmacare | -40.91% | 1.30% | -83.98% | -83.98% | -83.98% | -83.98% |
Performance & Financial Health Analysis: Beml Land Assets vs Johnson Pharmacare
| Metric | BLAL | JOHNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹8.67B | ₹434.50M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 43,864 | 1,020,557 |
| 90 Day Avg. Volume | 46,664 | 1,067,967 |
| Last Close | ₹208.52 | ₹0.78 |
| 52 Week Range | ₹180.50 - ₹292.50 | ₹0.76 - ₹1.44 |
| % from 52W High | -28.71% | -45.83% |
| All-Time High | ₹377.45 (Feb 05, 2024) | ₹7.14 (Jan 03, 2022) |
| % from All-Time High | -44.76% | -89.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | 1.28% |
| Return on Equity (TTM) | -3.38% | -0.01% |
| Debt to Equity (MRQ) | 779.28 | 1.08 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹0.27 | ₹1.09 |
| Cash per Share (MRQ) | ₹0.00 | ₹0.00 |
| Operating Cash Flow (TTM) | ₹8.68M | ₹-19,089,000 |
| Levered Free Cash Flow (TTM) | ₹-37,473,000 | ₹-5,838,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beml Land Assets vs Johnson Pharmacare
| Metric | BLAL | JOHNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -231.69 | -79.00 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -7.88 | 0.79 |
| Price to Sales (TTM) | N/A | -130.32 |
| Price to Book (MRQ) | 785.55 | 0.72 |
| Market Capitalization | ||
| Market Capitalization | ₹8.67B | ₹434.50M |
| Enterprise Value | ₹8.73B | ₹411.34M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | -123.38 |
| Enterprise to EBITDA | -256.50 | -99.79 |
| Risk & Other Metrics | ||
| Beta | 0.21 | -0.90 |
| Book Value per Share (MRQ) | ₹0.27 | ₹1.09 |
Financial Statements Comparison: Beml Land Assets vs Johnson Pharmacare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BLAL | JOHNPHARMA |
|---|---|---|
| Revenue/Sales | ₹0 | ₹0 |
| Cost of Goods Sold | ₹1.18M | ₹0 |
| Gross Profit | ₹-1.18M | ₹0 |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-2.25M | ₹-534,000 |
| EBITDA | ₹-2.07M | ₹-534,000 |
| Pre-Tax Income | ₹-4.19M | ₹-534,000 |
| Income Tax | ₹0 | N/A |
| Net Income (Profit) | ₹-4.19M | ₹-534,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BLAL | JOHNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹100,000 | ₹77,000 |
| Total Current Assets | ₹1.30M | ₹156.34M |
| Total Current Liabilities | ₹1.00M | ₹11.51M |
| Long-Term Debt | ₹0 | ₹6.05M |
| Total Shareholders Equity | ₹11.10M | ₹561.69M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BLAL | JOHNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BLAL | JOHNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 43,864 | 1,020,557 |
| Average Daily Volume (90 Day) | 46,664 | 1,067,967 |
| Shares Outstanding | 41.64M | 550.00M |
| Float Shares | 18.26M | 484.32M |
| % Held by Insiders | 0.54% | 0.06% |
| % Held by Institutions | 0.07% | 0.00% |
Dividend Analysis & Yield Comparison: Beml Land Assets vs Johnson Pharmacare
| Metric | BLAL | JOHNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |